Vol 27, No 6 (2020)
Original Article
Published online: 2019-05-29

open access

Page views 1160
Article views/downloads 1101
Get Citation

Connect on Social Media

Connect on Social Media

Echocardiographic assessment of tricuspid regurgitation and pericardial effusion after cardiac device implantation

Katarzyna Wiechecka1, Bartosz Wiechecki1, Agnieszka Kapłon-Cieślicka1, Agata Tymińska1, Monika Budnik1, Dominika Hołowaty1, Krzysztof Jakubowski1, Marcin Michalak1, Elżbieta Świętoń1, Przemysław Stolarz1, Roman Steckiewicz1, Marcin Grabowski1, Piotr Scisło1, Janusz Kochanowski1, Krzysztof J. Filipiak1, Grzegorz Opolski1
Pubmed: 31225634
Cardiol J 2020;27(6):797-806.


Background: The frequency of cardiac implantable electronic device (CIED) implantations is constantly increasing. Pericardial effusion (PE) and tricuspid regurgitation (TR) may occur after CIED implantation. The aim of the present study is to evaluate the prevalence and risk factors for new occurrences or progression of TR and PE early after CIED implantation.

Methods: This is an on-going, single-center, observational study of patients after their first CIED implantation, with an echocardiographic evaluation within 60 days before and 7 days after the procedure. Data are presented for first 110 consecutive patients who underwent CIED implantation from August 2015 to July 2016.

Results: Median age was 75 years, and 44% were women. In total, 87 (79%) pacemakers, 21 (19%) implantable cardioverter-defibrillators and 2 cardiac resynchronization therapy devices were implanted. After CIED implantation, there was TR progression in 17 (16%) patients: 5 patients developed moderate TR, none developed severe TR. An increase in TR was more often observed after implantations performed by operators in training than by certified operators (35% vs. 12%, p = 0.02). New PE after the procedure was observed in 8 (7%) patients and was trivial ( < 5 mm) in all cases. Patients with new PE after implantation had lower baseline hemoglobin levels and tended to be women.

Conclusions: New PE and an increase in TR severity are rare complications early after CIED implantation. Operator experience might be related to TR progression. Increasing the number of patients in the current on-going study will allow a more reliable assessment of the prevalence and risk factors of these complications.

Article available in PDF format

View PDF Download PDF file


  1. Aquilina O. A brief history of cardiac pacing. Images Paediatr Cardiol. 2006; 8(2): 17–81.
  2. Raatikainen MJ, Arnar DO, Zeppenfeld K, et al. Statistics on the use of cardiac electronic devices and electrophysiological procedures in the European Society of Cardiology countries: 2014 report from the European Heart Rhythm Association. Europace. 2015; 17 Suppl 1: i1–75.
  3. Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace. 2013; 15(8): 1070–1118.
  4. Gould L, Reddy CV, Yacob U, et al. Perforation of the tricuspid valve by a transvenous pacemaker. JAMA. 1974; 230(1): 86–87.
  5. Agarwal S, Tuzcu EM, Rodriguez ER, et al. Interventional cardiology perspective of functional tricuspid regurgitation. Circ Cardiovasc Interv. 2009; 2(6): 565–573.
  6. Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999; 83(6): 897–902.
  7. Paniagua D, Aldrich HR, Lieberman EH, et al. Increased prevalence of significant tricuspid regurgitation in patients with transvenous pacemakers leads. Am J Cardiol. 1998; 82(9): 1130–2, A9.
  8. Al-Bawardy R, Krishnaswamy A, Bhargava M, et al. Tricuspid regurgitation in patients with pacemakers and implantable cardiac defibrillators: a comprehensive review. Clin Cardiol. 2013; 36(5): 249–254.
  9. Champagne J, Poirier P, Dumesnil JG, et al. Permanent pacemaker lead entrapment: role of the transesophageal echocardiography. Pacing Clin Electrophysiol. 2002; 25(7): 1131–1134.
  10. Gawalko M, Kołodzińska A, Grabowski M, et al. Transvenous lead removal with a fragment of a papillary muscle - a silent complication. Heart Beat J. 2017; 1: 41–42.
  11. Roeffel S, Bracke F, Meijer A, et al. Transesophageal echocardiographic evaluation of tricuspid valve regurgitation during pacemaker and implantable cardioverter defibrillator lead extraction. Pacing Clin Electrophysiol. 2002; 25(11): 1583–1586.
  12. Zawadzki J, Januszkiewicz Ł, Cacko A, et al. Left Ventricular Pacing via Coronary Sinus in a Patient With a Mechanical Tricuspid Valve. Heart Beat J. 2017; 2: 36–37.
  13. Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol. 2004; 43(3): 405–409.
  14. Höke U, Auger D, Thijssen J, et al. Significant lead-induced tricuspid regurgitation is associated with poor prognosis at long-term follow-up. Heart. 2014; 100(12): 960–968.
  15. Rothschild DP, Goldstein JA, Kerner N, et al. Pacemaker-induced tricuspid regurgitation is uncommon immediately post-implantation. J Interv Card Electrophysiol. 2017; 49(3): 281–287.
  16. Arabi P, Özer N, Ateş AH, et al. Effects of pacemaker and implantable cardioverter defibrillator electrodes on tricuspid regurgitation and right sided heart functions. Cardiol J. 2015; 22(6): 637–644.
  17. Fanari Z, Hammami S, Hammami MB, et al. The effects of right ventricular apical pacing frequency on left ventricle function and pulmonary artery pressure. Del Med J. 2015; 87(8): 244–247.
  18. Ohlow MA, Lauer B, Brunelli M, et al. Incidence and predictors of pericardial effusion after permanent heart rhythm device implantation: prospective evaluation of 968 consecutive patients. Circ J. 2013; 77(4): 975–981.
  19. Lancellotti P, Tribouilloy C, Hagendorff A, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2013; 14(7): 611–644.
  20. Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015; 36(42): 2921–2964.
  21. Klutstein M, Balkin J, Butnaru A, et al. Tricuspid incompetence following permanent pacemaker implantation. Pacing Clin Electrophysiol. 2009; 32 Suppl 1: S135–S137.
  22. Webster G, Margossian R, Alexander ME, et al. Impact of transvenous ventricular pacing leads on tricuspid regurgitation in pediatric and congenital heart disease patients. J Interv Card Electrophysiol. 2008; 21(1): 65–68.
  23. Postaci N, Ekşi K, Bayata S, et al. Effect of the number of ventricular leads on right ventricular hemodynamics in patients with permanent pacemaker. Angiology. 1995; 46(5): 421–424.
  24. Al-Bawardy R, Krishnaswamy A, Rajeswaran J, et al. Tricuspid regurgitation and implantable devices. Pacing Clin Electrophysiol. 2015; 38(2): 259–266.
  25. Kim JB, Spevack DM, Tunick PA, et al. The effect of transvenous pacemaker and implantable cardioverter defibrillator lead placement on tricuspid valve function: an observational study. J Am Soc Echocardiogr. 2008; 21(3): 284–287.
  26. Lin G, Nishimura RA, Connolly HM, et al. Severe symptomatic tricuspid valve regurgitation due to permanent pacemaker or implantable cardioverter-defibrillator leads. J Am Coll Cardiol. 2005; 45(10): 1672–1675.
  27. Michniewicz E, Mlodawska E, Lopatowska P, et al. Patients with atrial fibrillation and coronary artery disease - Double trouble. Adv Med Sci. 2018; 63(1): 30–35.
  28. Tomaszuk-Kazberuk A, Kołtowski L, Balsam P, et al. Use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation - Messages from the 2018 EHRA. Cardiol J. 2018; 25(4): 423–440.
  29. Tompkins C, Cheng A, Dalal D, et al. Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol. 2010; 55(21): 2376–2382.
  30. Tettey M, Aniteye E, Sereboe L, et al. Predictors of post operative bleeding and blood transfusion in cardiac surgery. Ghana Med J. 2009; 43(2): 71–76.
  31. Kalra PR, Greenlaw N, Ferrari R, et al. Hemoglobin and change in hemoglobin status predict mortality, cardiovascular events, and bleeding in stable coronary artery disease. Am J Med. 2017; 130(6): 720–730.